login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

New drug may block the effects of traumatic brain injury


Wednesday, 22 Feb 2012 15:20

A new drug called clazosentan is showing promise in blocking the harmful effects of traumatic brain injury in rats, according to a study to be presented at the American Academy of Neurology’s 64th Annual Meeting in New Orleans, USA, (21–28 April 2012).


“There are currently no primary treatments for traumatic brain injury, so this research provides hope that effective treatments can be developed,” said study author Michael Kaufman, a second year medical student at Wayne State University School of Medicine in Detroit and a member of the American Academy of Neurology. The principal investigator on the study is Christian Kreipke, also from Wayne State University School of Medicine.


Traumatic brain injury causes a decrease in blood flow in the cerebrum of the brain, which if prolonged, can cause permanent cell dysfunction and death. A receptor in the brain called endothelin receptor (ETrA) contributes to the restriction of blood flow as early as four hours after a brain injury. The new drug, called clazosentan, is thought to specifically block these receptors.


Researchers gave brain-injured rats the drug clazosentan through an intravenous line at several different points in time after the injury. Next, they measured the rat’s blood flow in the hippocampus and sensory motor cortex with an MRI brain scan and tested their behavior in learning a maze.


Preliminary data from the study found that clazosentan decreased the effects of the traumatic brain injury on blood flow to the hippocampus by 25% at four hours and 23% at 48 hours after traumatic brain injury. However, giving the rats the drug at 12 hours post-injury caused some to improve, while others worsened or remained the same. In the trial, the drug was most effective when given at two hours post-injury and again at 24 hours after the trauma. The rats also performed better on the maze test when given the drug at two and 24 hours post-injury.


“This research is the foundation for future clinical trials that will investigate the possibilities of using clazosentan in the treatment of traumatic brain injury,” said Kaufman.


The study was supported by the American Academy of Neurology, the National Institutes of Health, and the US Department of Veterans Affairs.




Add New Comment

Most popular


New device allows brain to bypass spinal cord and move paralysed limbs
Friday, 27 Jun 2014
For the first time ever, a paralysed man has moved his fingers and hand with his own thoughts after an electronic neural bypass for spinal cord injuries that reconnects the brain directly to muscles, ... New device allows brain to bypass spinal cord and move paralysed limbs

FDA IDE approval for PulseRider
Tuesday, 10 Jun 2014
The IDE allows Pulsar Vascular to begin a multicentre clinical trial in support of a humanitarian device exemption (HDE) to evaluate the PulseRider for US approval for wide neck aneurysms at or near ... FDA IDE approval for PulseRider

ROADSTER trial studying new path to carotid revascularisation completes patient enrolment
Friday, 18 Jul 2014
The trial was the first of its kind to study the treatment of carotid artery stenosis by placing a stent via direct access to the common carotid artery in the neck in an entirely new minimally ... ROADSTER trial studying new path to carotid revascularisation completes patient enrolment

Features


Neuro-oncologic treatment for glioblastoma
Monday, 21 Jul 2014
Malignant gliomas are the most common type of primary malignant brain tumour, accounting for 80% of patients and an annual incidence of 5.26 per 100,000 population, or 17,000 new cases diagnosed per ... Neuro-oncologic treatment for glioblastoma

Early brain stimulation may help stroke survivors recover language function
Monday, 21 Jul 2014
Dieter Heiss, who presented on early brain stimulation for stroke patients at the 8th World Congress on Controversies in Neurology (CONy), 8–11 May, Berlin, Germany, writes for NeuroNews on how this ... Early brain stimulation may help stroke survivors recover language function

Profiles


Mauricio Castillo
Monday, 14 Jul 2014
Mauricio Castillo is a professor of Radiology and chief, Division of Neuroradiology, University of N... Mauricio Castillo

William T Couldwell
Thursday, 24 Apr 2014
William T Couldwell is professor of neurosurgery in the Department of Neurological Surgery, U... William T Couldwell

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions